The exogenously driven disruption of Bioprocessing

15th September 2022 | 10:00am EST / 3:00pm GMT / 4:00pm CET | Presented by Christos Varsakelis, Team Lead Artificial Intelligence/Machine Learning at The Janssen Pharmaceutical Companies of Johnson & Johnson |BOOK FREE SEAT FOR THIS WEBINAR

Industry 4.0 comes with an impressive collection of assets and capabilities. However, although the degree of applicability in Bioprocessing is high, the origin of these technological innovations is exogenous. This is not without implications and in this talk, we are concerned with their identification and quantification. We commence with the onboarding of an exogenous technology problem. Industry 4.0 tools have been developed with different objectives in mind. Integrating them in Bioprocessing requires a critical a priori analysis of similarities and transferability. We then move on to address a fundamental question: is this exogeneity positive or negative for Bioprocessing?  The answer is drawn from historical case studies, stemming from different industries. This naturally leads us to the concept of the fallacy of division and the associated dangers of disruption. Finally, we go a step further and explore how the addition of 4.0 in Bioprocessing can alter the core business activities and what this implies for the insourcing vs outsourcing dilemma that both big and small corporations have to face.

Presented by Christos Varsakelis, Team Lead Artificial Intelligence/Machine Learning at The Janssen Pharmaceutical Companies of Johnson & Johnson

Christos Varsakelis leads the AI/ML team for Drug Discovery in the Janssen Pharmaceutical Companies aiming at the acceleration of development timelines and increase of probability of technical success. Prior joining Janssen, Christos was a Senior Manager of Global Analytics & Innovation in GSK Vaccines focusing on in silico Bioprocess development. Besides working in the pharmaceutical industry, Christos has accumulated professional experience that spans across Geoconsulting, the stock market and the chemical industry. Christos is in hold of a Ph.D. in fluid mechanics in UCLouvain in Belgium. He is also in hold of a B.A. in Mathematics from the Aristotle University of Thessaloniki, Greece and an M.Sc. in Applied Mathematics from the ETH Zurich, Switzerland. His moto is innovation = cash.

Sponsored by Insilico



Insilico Biotechnology AG develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality, and process robustness. Groundbreaking predictive power is achieved by exploiting process data using machine learning and models of biochemical networks. As a result, Insilico’s unique approach substantially reduces experimental effort, costs of goods, and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design, and process control. Founded in 2001, Insilico Biotechnology AG is a privately held company based in Stuttgart, Germany.

We will not sell your information to a third party. See our Privacy Policy